Eckert & Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from Bioscan, Inc.
Eckert & Ziegler Strahlen- und Medizintechnik AG has entered into an agreement with Bioscan, Inc., located in Washington, D.C., to acquire its radiopharmaceutical equipment business. The transaction involves both analytical instruments used in quality assurance of radioactive pharmaceuticals and automated radiopharmaceutical synthesis units. Such equipment is used worldwide in the production of radiolabeled molecular imaging agents used in nuclear medicine.
Eckert & Ziegler Radiopharma Board member, Dr. André Heß, explained: "The products we have acquired ideally enhance our developing equipment business and ensure we can offer our customers system solutions for the production and quality assurance of radiopharmaceuticals. By such an investment we are broadening our commitment to the North American market."
"Bioscan has been a leading player in radioanalytic and radiochemistry instrumentation for more than thirty years. Over the past five years, the company has increasingly focused on its fast-growing molecular imaging business", commented Alex Kleinman, Vice President of Marketing and Business Development for Bioscan. "Today's transaction will enable Bioscan to increase investment in its rapidly expanding preclinical imaging product line. We are pleased to be able to entrust our radiopharmaceutical equipment business and the thousands of customers that use Bioscan radioanalytic and radiochemistry instruments every day to a market leader like Eckert & Ziegler."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Late_Quaternary_prehistoric_birds
Merck Completes Acquisition of Exelead and Plans to Invest More Than € 500 Million in Technology Scale-Up - Company now offers comprehensive end-to-end services across mRNA value chain
Dako and Quintiles form alliance to speed development of personalized medicine
Genes in female and male hearts react differently to heart valve defects
Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
How antibiotics interact - Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics
Spider venom for therapeutics and bioinsecticides - New biomolecules from wasp spider venom
Herpesviridae
Labcyte Granted Patent for Acoustic Transfer of Living Cells and Solid Particles
Dog_health
